Market Cap 361.73M
Revenue (ttm) 0.00
Net Income (ttm) -37.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 45,886
Avg Vol 50,220
Day's Range N/A - N/A
Shares Out 26.25M
Stochastic %K 75%
Beta 0.41
Analysts Strong Sell
Price Target $24.86

Company Profile

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene thera...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 780 0819
Website: benitec.com
Address:
3940 Trust Way, Hayward, United States
BOXLinvestor
BOXLinvestor Oct. 9 at 5:17 AM
$BNTC Benitec Biopharma (stock volume 10-08-25) 14.10 +2.3% | volume 501,789 | 90-day avg 90,061 × 5.6
0 · Reply
Doozio
Doozio Oct. 8 at 5:43 PM
$BNTC are those 🧠 blocks?
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 6 at 4:03 PM
$BNTC Great piece that accurately captures BNTC's current position. So if you want to refresh your understanding of BNTC or learn about BNTC for the first time, this is essential reading. https://beyondspx.com/quote/BNTC/analysis/benitec-biopharma-unveiling-the-promise-of-silence-and-replace-gene-therapy-in-orphan-diseases-nasdaq-bntc
0 · Reply
Doozio
Doozio Oct. 3 at 9:38 PM
$BNTC chop chop huckleberries. Out of the tightness da 🧠 shall spread. 🐒🍌🧠⏰♾️
1 · Reply
JoshThe3rd
JoshThe3rd Oct. 3 at 9:27 PM
$BNTC I feel like I should be more long.
0 · Reply
JarvisFlow
JarvisFlow Sep. 24 at 1:03 PM
JMP Securities has adjusted their stance on Benitec Biopharma ( $BNTC ), setting the rating to Market Outperform with a target price of 20.
0 · Reply
ChessGM
ChessGM Sep. 18 at 8:57 PM
"Heads up alert! Upcoming earnings on Friday, 9/26/2025 for $BNTC Bearish (2.8) Equity Research Report: Benitec Biopharma (NASDAQ:BNTC) Benitec Biopharma, a biotechnology company specializing in RNA interference-based therapeutics, currently faces a challenging market environment as reflected in its declining stock performance. The company's price-to-earnings (P/E) ratio is currently negative, indicating that it is not generating positive earnings, a common scenario for biotech firms in the R&D phase. This situation is further exacerbated by a stagnant or diminishing earnings per share (EPS) growth, which signals that the company is facing hurdles in advancing its pipeline to revenue-generating stages. Revenue forecasts for Benitec Biopharma remain speculative at best, as the company has yet to commercialize any of its therapeutic candidates. Compared to industry peers, Benitec appears to be lagging in terms of both pipeline advancement and strategic partnerships that are vital for accelerating clinical trials and commercialization efforts. Additionally, Benitec's financial position reveals a considerable cash reserve; however, the burn rate associated with ongoing research and development could deplete resources quickly if effective commercialization strategies are not implemented soon. Earnings Report Overview: Looking ahead to upcoming earnings reports, analysts are not expecting significant deviations from the current trajectory. Historical performance has shown consistent losses with minimal or no revenue reported, primarily due to the developmental nature of the company's operations. Consensus estimates suggest that Benitec will continue to report losses in the near term. The impact on the stock could be minimal unless there is a surprise announcement regarding a breakthrough in clinical trials or a valuable partnership deal. It is crucial for investors to monitor updates on the company's pipeline progress and any strategic initiatives that might alter the current financial outlook. Sector Performance: Benitec Biopharma operates within the biotechnology sector, which has been experiencing mixed performance recently. While the sector as a whole benefits from innovations and advancements in medical technologies, individual companies often face high volatility due to the binary nature of clinical trial outcomes and regulatory approvals. Larger biotech firms with diversified pipelines and multiple revenue streams have generally fared better, while smaller entities like Benitec are more susceptible to market fluctuations and investor sentiment shifts. The overall sector is showing signs of cautious optimism, but individual stock performance remains heavily dependent on specific company milestones and news flow. - Funds were net buyers of $BNTC during the previous reporting quarter. - Funds with large holdings in $BNTC include: - Suvretta Capital Management LLC, MV: $116MM. Fund Rank: 78% www.suvcap.com - Adage Capital P, MV: $23MM. Fund Rank: 87% www.adagecapital.com - Nantahala Capital Management LLC, MV: $10MM. Fund Rank: 65% www.nantahalapartners.com - Last 10 days performance: -1% - Last 30 days performance: 9% - Last 90 days performance: -6% Some of the latest news articles: - Title: We're Interested To See How Benitec Biopharma (NASDAQ:BNTC) Uses Its Cash Hoard To Grow Publication Date: 8/17/2025 12:02:18 PM, Source: yahoo URL: https://finance.yahoo.com/news/were-interested-see-benitec-biopharma-120218861.html?.tsrc=rss Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."
0 · Reply
RealAvidTrader
RealAvidTrader Sep. 17 at 2:20 PM
$AUTL $BNTC $DMAC MUST WATCH 🤩🤩🤩
0 · Reply
RealAvidTrader
RealAvidTrader Sep. 16 at 5:20 PM
$DMAC $AUTL $BNTC Insiders Are Buying MILLIONS of This Stock! What Do They Know? https://youtu.be/kSulwCUgoOU
0 · Reply
Moneymastermind99
Moneymastermind99 Sep. 4 at 11:45 PM
0 · Reply
Latest News on BNTC
Benitec Biopharma Releases Q3 2022 Financial Results

May 16, 2022, 8:15 AM EDT - 3 years ago

Benitec Biopharma Releases Q3 2022 Financial Results


Benitec Biopharma Discloses Q2 2022 Financial Results

Feb 14, 2022, 8:00 AM EST - 3 years ago

Benitec Biopharma Discloses Q2 2022 Financial Results


Benitec Biopharma Discloses Q1 2022 Financial Results

Nov 15, 2021, 8:00 AM EST - 4 years ago

Benitec Biopharma Discloses Q1 2022 Financial Results


Benitec BioPharma Shares Rally: Technical Levels To Watch

Mar 23, 2021, 5:03 PM EDT - 4 years ago

Benitec BioPharma Shares Rally: Technical Levels To Watch


Why DLPN Stock And BNTC Stock Are Popping Off Today

Mar 23, 2021, 11:28 AM EDT - 4 years ago

Why DLPN Stock And BNTC Stock Are Popping Off Today

DLPN


Why Benitec Biopharma (BNTC) Stock Is Skyrocketing Today

Mar 23, 2021, 5:20 AM EDT - 4 years ago

Why Benitec Biopharma (BNTC) Stock Is Skyrocketing Today


Benitec Biopharma Announces 2020 Annual Stockholder Meeting

Dec 7, 2020, 2:33 PM EST - 5 years ago

Benitec Biopharma Announces 2020 Annual Stockholder Meeting


BOXLinvestor
BOXLinvestor Oct. 9 at 5:17 AM
$BNTC Benitec Biopharma (stock volume 10-08-25) 14.10 +2.3% | volume 501,789 | 90-day avg 90,061 × 5.6
0 · Reply
Doozio
Doozio Oct. 8 at 5:43 PM
$BNTC are those 🧠 blocks?
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 6 at 4:03 PM
$BNTC Great piece that accurately captures BNTC's current position. So if you want to refresh your understanding of BNTC or learn about BNTC for the first time, this is essential reading. https://beyondspx.com/quote/BNTC/analysis/benitec-biopharma-unveiling-the-promise-of-silence-and-replace-gene-therapy-in-orphan-diseases-nasdaq-bntc
0 · Reply
Doozio
Doozio Oct. 3 at 9:38 PM
$BNTC chop chop huckleberries. Out of the tightness da 🧠 shall spread. 🐒🍌🧠⏰♾️
1 · Reply
JoshThe3rd
JoshThe3rd Oct. 3 at 9:27 PM
$BNTC I feel like I should be more long.
0 · Reply
JarvisFlow
JarvisFlow Sep. 24 at 1:03 PM
JMP Securities has adjusted their stance on Benitec Biopharma ( $BNTC ), setting the rating to Market Outperform with a target price of 20.
0 · Reply
ChessGM
ChessGM Sep. 18 at 8:57 PM
"Heads up alert! Upcoming earnings on Friday, 9/26/2025 for $BNTC Bearish (2.8) Equity Research Report: Benitec Biopharma (NASDAQ:BNTC) Benitec Biopharma, a biotechnology company specializing in RNA interference-based therapeutics, currently faces a challenging market environment as reflected in its declining stock performance. The company's price-to-earnings (P/E) ratio is currently negative, indicating that it is not generating positive earnings, a common scenario for biotech firms in the R&D phase. This situation is further exacerbated by a stagnant or diminishing earnings per share (EPS) growth, which signals that the company is facing hurdles in advancing its pipeline to revenue-generating stages. Revenue forecasts for Benitec Biopharma remain speculative at best, as the company has yet to commercialize any of its therapeutic candidates. Compared to industry peers, Benitec appears to be lagging in terms of both pipeline advancement and strategic partnerships that are vital for accelerating clinical trials and commercialization efforts. Additionally, Benitec's financial position reveals a considerable cash reserve; however, the burn rate associated with ongoing research and development could deplete resources quickly if effective commercialization strategies are not implemented soon. Earnings Report Overview: Looking ahead to upcoming earnings reports, analysts are not expecting significant deviations from the current trajectory. Historical performance has shown consistent losses with minimal or no revenue reported, primarily due to the developmental nature of the company's operations. Consensus estimates suggest that Benitec will continue to report losses in the near term. The impact on the stock could be minimal unless there is a surprise announcement regarding a breakthrough in clinical trials or a valuable partnership deal. It is crucial for investors to monitor updates on the company's pipeline progress and any strategic initiatives that might alter the current financial outlook. Sector Performance: Benitec Biopharma operates within the biotechnology sector, which has been experiencing mixed performance recently. While the sector as a whole benefits from innovations and advancements in medical technologies, individual companies often face high volatility due to the binary nature of clinical trial outcomes and regulatory approvals. Larger biotech firms with diversified pipelines and multiple revenue streams have generally fared better, while smaller entities like Benitec are more susceptible to market fluctuations and investor sentiment shifts. The overall sector is showing signs of cautious optimism, but individual stock performance remains heavily dependent on specific company milestones and news flow. - Funds were net buyers of $BNTC during the previous reporting quarter. - Funds with large holdings in $BNTC include: - Suvretta Capital Management LLC, MV: $116MM. Fund Rank: 78% www.suvcap.com - Adage Capital P, MV: $23MM. Fund Rank: 87% www.adagecapital.com - Nantahala Capital Management LLC, MV: $10MM. Fund Rank: 65% www.nantahalapartners.com - Last 10 days performance: -1% - Last 30 days performance: 9% - Last 90 days performance: -6% Some of the latest news articles: - Title: We're Interested To See How Benitec Biopharma (NASDAQ:BNTC) Uses Its Cash Hoard To Grow Publication Date: 8/17/2025 12:02:18 PM, Source: yahoo URL: https://finance.yahoo.com/news/were-interested-see-benitec-biopharma-120218861.html?.tsrc=rss Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."
0 · Reply
RealAvidTrader
RealAvidTrader Sep. 17 at 2:20 PM
$AUTL $BNTC $DMAC MUST WATCH 🤩🤩🤩
0 · Reply
RealAvidTrader
RealAvidTrader Sep. 16 at 5:20 PM
$DMAC $AUTL $BNTC Insiders Are Buying MILLIONS of This Stock! What Do They Know? https://youtu.be/kSulwCUgoOU
0 · Reply
Moneymastermind99
Moneymastermind99 Sep. 4 at 11:45 PM
0 · Reply
Moneymastermind99
Moneymastermind99 Sep. 4 at 9:07 PM
$BDSX – Load the Boat & Fasten Your Seatbelt Biodesix is sitting at ~$0.44, but the setup is screaming “explosive move”: analysts average $1.75 (range $1.50–$2.10), implying 300–350% upside. Short interest is high (~3.8M shares; 2.6 days to cover; 18% borrow fee), and float is tight—classic squeeze fuel. Recent intraday surges (up near $0.61) on solid volume hint this isn’t dead money. If ASCO or NGS catalyst hits, once it goes, it goes fast. Keeping an eye on similar small-cap catalysts like $BNTC, $APRE, $SLNO, $IMMX. Not financial advice—just spreading info for momentum-seekers. #BDSX #Biotech #Diagnostics #ShortSqueeze #LoadTheBoat #Stocks #MomentumPlay
0 · Reply
Moneymastermind99
Moneymastermind99 Sep. 4 at 6:46 PM
🚀 Biodesix (BDSX) Bullish Setup 🚀 Trading near $0.45, BDSX ripped after major holder Jack Schuler bought 3.49M shares ($1.5M), raising his stake to 26%—a strong insider confidence play. Q2 revenue hit $20M (+12% YoY) with 80% margins, guidance reaffirmed at $80–85M. Analysts call it a Strong Buy with PT $1.75 (~300% upside). 📊 Similar small-cap biotech/diagnostic movers: $BNTC, $APRE, $SLNO, $IMMX. #BDSX #Biotech #InsiderBuying #StrongBuy #SmallCap #Diagnostics
0 · Reply
Moneymastermind99
Moneymastermind99 Sep. 4 at 6:45 PM
🚀 Biodesix (BDSX) Bullish Setup 🚀 Trading near $0.45, BDSX ripped after major holder Jack Schuler bought 3.49M shares ($1.5M), raising his stake to 26%—a strong insider confidence play. Q2 revenue hit $20M (+12% YoY) with 80% margins, guidance reaffirmed at $80–85M. Analysts call it a Strong Buy with PT $1.75 (~300% upside). 📊 Similar small-cap biotech/diagnostic movers: $BNTC, $APRE, $SLNO, $IMMX. #BDSX #Biotech #InsiderBuying #StrongBuy #SmallCap #Diagnostics
0 · Reply
smoketuna
smoketuna Aug. 28 at 4:20 PM
$BNTC 85% with 🎯 TunaSignal.ai score! while price $13.15 - Catch the Big Movers Before They Break Out - Powered by AI
0 · Reply
MomentumMonarch
MomentumMonarch Aug. 23 at 7:46 AM
$BNTC Benitec Biopharma Inc is a gene therapy company with early stage pipeline and funding needs
0 · Reply
Bullshyte
Bullshyte Aug. 4 at 7:14 AM
$BNTC tremendously
0 · Reply
mosu_trader
mosu_trader Aug. 3 at 9:33 PM
$BNTC TP1: 12 , TP2: 12.8
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 28 at 8:27 PM
$BNTC Really good write-up that perfectly summarizes BNTC's present situation. So if you want to bring your BNTC knowledge up to date or just discover BNTC, this is required reading. https://beyondspx.com/article/benitec-biopharma-unpacking-the-silence-and-replace-gene-therapy-opportunity-bntc
0 · Reply
DARKP00L
DARKP00L Jul. 9 at 12:20 PM
$BNTC 08:18 on Jul. 09 2025 Benitec Biopharma Receives Green Light To Advance BB-301 Trial After Safety Review; Cohort 2 Enrollment Set For Q4 2025 #tradeideas
0 · Reply
DARKP00L
DARKP00L Jul. 9 at 12:18 PM
$BNTC 08:18 on Jul. 09 2025 Benitec Biopharma Receives Green Light To Advance BB-301 Trial After Safety Review; Cohort 2 Enrollment Set For Q4 2025 #tradeideas
0 · Reply
JoshThe3rd
JoshThe3rd Jun. 27 at 6:39 PM
$BNTC an institution is liquidating. Will probably bounce off the 200MA daily when selling is done.
1 · Reply